<DOC>
	<DOCNO>NCT00601107</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness investigational drug call doxercalciferol participant moderate severe chronic plaque psoriasis , comparison placebo ( `` sugar pill '' ) . All study relate care provide include doctor visit , physical exam , laboratory test study medication . Total length participation 28 week .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Doxercalciferol Capsules Participants With Moderate Severe Psoriasis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , dose-ranging , parallel group study evaluate efficacy safety doxercalciferol give orally , daily 24 week participant moderate severe chronic plaque psoriasis . Participants randomize stratified site Psoriasis Area Severity Index ( PASI ) score one three active treatment group placebo group .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Participant moderate severe chronic plaque psoriasis define body surface area ( BSA ) involvement great equal ( &gt; = ) 10 percent ( % ) plaques least slight elevation surround normal skin Day 1 visit Participant static Physician 's Global Assessment ( PGA ) moderate severe Day 1 visit Participant minimum PASI score 10 Day 1 visit Participant candidate receive systemic psoriasis therapy opinion Investigator Participant childbearing potential , willing use effective contraceptive method throughout study , include barrier method , hormone , intrauterine device Used vitamin D analogue , multivitamin supplement contain great ( &gt; ) 400 international unit ( IU ) vitamin D , topical retinoids , topical pimecrolimus , topical tacrolimus within 14 day prior Day 1 visit Used drug know influence serum calcium ( lithium , digoxin , thiazide diuretic , teriparatide , bisphosphonates , calcitonin ) multivitamin supplement contain calcium and/or calciumcontaining antacid exceed total 1 gram/day within 14 day prior Day 1 visit Used keratolytics coal tar ( except shampoo contain coal tar salicylic acid ) within 14 day prior Day 1 visit Used low potency topical corticosteroid ( Classes VI VII ) , except groin , scalp , palm , sol face , within 14 day prior Day 1 visit Used medium potency topical corticosteroid ( Classes III V ) high potency topical corticosteroid ( Classes I II ) within 14 day prior Day 1 visit Used systemic retinoids , systemic corticosteroid , methotrexate , cyclosporine , azathioprine , thioguanine systemic immunosuppressant agent within 28 day prior Day 1 visit Used phototherapy , include Ultraviolet B within 14 day Psoralen plus Ultraviolet A within 28 day prior Day 1 visit Used biological agent ( include , limited , etanercept , adalimumab , efalizumab , infliximab , alefacept ) within 5 halflives drug prior Day 1 visit Used systemic antibiotic within 14 day prior Day 1 visit . Antibiotic treatment infection Treatment Period exclude Used investigational drug within 28 day prior Day 1 visit Current erythrodermic , guttate , generalize pustular , unstable psoriasis chronic active skin condition may interfere study Screening visit laboratory result exceed follow limit : alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) ; bilirubin &gt; ULN ; serum creatinine , calcium , phosphorus &gt; ULN ; spot urine calcium/creatinine ratio &gt; 0.4 History nephrolithiasis Chronic kidney disease evidence calculated glomerular filtration rate ( GFR ) less ( &lt; ) 60 milliliter/minute/1.73 square meter ( mL/min/1.73 m^2 ) screen visit Symptomatic coronary cerebral vascular disease , human immunodeficiency virus , active viral hepatitis , clinically significant , unstable medical condition would interfere completion study Clinically significant electrocardiogram ( EKG ) abnormality screen Any evidence active malignancy except basal cell carcinoma skin . A history malignancy exclusion Active ethanol drug abuse , exclude tobacco use Active severe psychiatric illness could interfere conduct study Pregnant breastfeed woman Known allergy hypersensitivity vitamin D ingredient study drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>psoriasis vulgaris</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>chronic plaque psoriasis</keyword>
</DOC>